
Bristol-Myers Squibb Company BMY
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
2.03 B |
Market Cap[1] |
$ 128 B |
EBITDA (LTM) |
$ 2.33 B |
P/E (LTM) |
13.467991 |
P/S (LTM) |
2.48025 |
EPS (LTM) |
4.53 |
Bristol-Myers Squibb (BMY) is an international pharmaceutical company that specializes in the development and production of medicinal products for the treatment of various diseases, including oncology, cardiology, immunology, and other areas of medicine. The company was founded in 1858 and has its headquarters in New York.
Bristol-Myers Squibb is a leader in the pharmaceutical industry and has a wide range of products, including well-known brands such as Opdivo, Eliquis, Orencia, and Sprycel. It is also actively engaged in research and development of new medicinal products to help patients with various diseases.
The company aims to be socially responsible and sustainable and has set ambitious goals to reduce its impact on the environment. It also supports numerous philanthropic programs, including programs to combat cancer and other diseases.
However, like any pharmaceutical company, BMY faces criticism from those who claim that drug prices are too high and that the company is not doing enough to ensure accessibility of drugs for all patients. The company claims to be working on addressing this issue and striving to make its products more accessible to everyone.
Overall, Bristol-Myers Squibb is a large and respected pharmaceutical company that is actively engaged in developing medicinal products for the treatment of various diseases. It also aims to be socially responsible and sustainable and supports numerous philanthropic programs. However, the company faces challenges related to drug accessibility for all patients and is working on addressing this issue.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Repare Therapeutics
RPTX
|
- | - | $ 112 M | Nasdaq Global Select Market | ||
|
Sesen Bio
SESN
|
- | 7.29 % | $ 127 M | Nasdaq Global Select Market | ||
|
Windtree Therapeutics
WINT
|
- | - | $ 26.8 M | Nasdaq Global Select Market | ||
|
Trean Insurance Group
TIG
|
- | - | $ 316 M | Nasdaq Global Select Market | ||
|
SQZ Biotechnologies Company
SQZ
|
- | 57.95 % | $ 12.8 M | NYSE | ||
|
MEI Pharma
MEIP
|
- | 10.43 % | $ 20.5 M | Nasdaq Capital Market | ||
|
Palatin Technologies
PTN
|
- | - | $ 13 M | NYSE American | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
ММЦБ
GEMA
|
- | - | - | MOEX | ||
|
Lyra Therapeutics
LYRA
|
- | - | $ 24.9 M | Nasdaq Global Market | ||
|
ОЗОН Фармацевтика
OZPH
|
- | - | - | MOEX | ||
|
Промомед
PRMD
|
- | - | - | MOEX | ||
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
ESSA Pharma
EPIX
|
- | - | $ 8.86 M | Nasdaq Capital Market | ||
|
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | ||
|
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | ||
|
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market | ||
|
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | ||
|
Annexon
ANNX
|
$ 4.0 | -7.62 % | $ 620 M | Nasdaq Global Select Market | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 156.5 | -2.85 % | $ 20.5 B | Nasdaq Global Select Market,SPB | ||
|
Amgen
AMGN
|
$ 462.71 | -3.3 % | $ 249 B | Nasdaq Global Select Market,SPB | ||
|
Theratechnologies
THTX
|
- | - | $ 83.9 M | Nasdaq Capital Market | ||
|
Iovance Biotherapeutics
IOVA
|
$ 7.72 | -11.26 % | $ 2.76 M | Nasdaq Global Market,SPB | ||
|
Biogen
BIIB
|
$ 243.85 | -4.17 % | $ 35.7 B | Nasdaq Global Select Market,SPB | ||
|
Ironwood Pharmaceuticals
IRWD
|
$ 4.03 | 6.9 % | $ 652 M | Nasdaq Global Select Market | ||
|
Armata Pharmaceuticals
ARMP
|
$ 3.01 | -4.14 % | $ 109 M | NYSE American | ||
|
Mustang Bio
MBIO
|
$ 0.39 | -5.63 % | $ 1.91 M | Nasdaq Global Market | ||
|
MannKind Corporation
MNKD
|
$ 3.77 | -4.07 % | $ 1.15 B | Nasdaq Global Market | ||
|
InflaRx N.V.
IFRX
|
$ 1.36 | -8.11 % | $ 91.5 M | Nasdaq Global Select Market | ||
|
Immutep Limited
IMMP
|
$ 2.7 | -8.47 % | $ 3.93 B | Nasdaq Global Market | ||
|
Insmed Incorporated
INSM
|
$ 108.79 | -1.1 % | $ 21.7 B | Nasdaq Global Select Market | ||
|
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | Nasdaq Capital Market | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
$ 227.25 | -3.16 % | $ 13.9 B | Nasdaq Global Select Market | ||
|
BioLineRx Ltd.
BLRX
|
$ 1.77 | -4.95 % | $ 4.36 B | Nasdaq Capital Market | ||
|
Johnson & Johnson
JNJ
|
$ 272.47 | -1.4 % | $ 656 B | NYSE,SPB | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
PainReform Ltd.
PRFX
|
$ 0.76 | -1.27 % | $ 492 K | Nasdaq Capital Market | ||
|
Kala Pharmaceuticals
KALA
|
$ 0.15 | -13.14 % | $ 1.22 M | Nasdaq Global Select Market | ||
|
Prothena Corporation plc
PRTA
|
$ 7.9 | -5.84 % | $ 425 M | Nasdaq Global Select Market,SPB | ||
|
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | Nasdaq Global Select Market,SPB | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
$ 14.53 | -1.63 % | $ 12.1 B | NYSE | ||
|
Keros Therapeutics
KROS
|
$ 9.42 | -13.02 % | $ 351 M | Nasdaq Global Select Market | ||
|
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | ||
|
Kazia Therapeutics Limited
KZIA
|
$ 7.13 | -11.76 % | $ 109 M | Nasdaq Global Select Market | ||
|
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | Nasdaq Global Select Market | ||
|
Sana Biotechnology
SANA
|
$ 2.32 | -9.38 % | $ 588 M | Nasdaq Global Select Market | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.98 | -4.85 % | $ 226 M | NYSE American | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
$ 298.8 | -5.48 % | $ 5.78 B | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.